Literature DB >> 29167906

Ceftriaxone-induced pseudolithiasis: not just a theoretical risk.

Lijia Fan1, Perry Lau1, Jeevesh Kapur2, Sivaramakrishnan Venkatesh Karthik1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29167906      PMCID： PMC5691233          DOI： 10.11622/smedj.2017103

Source DB:  PubMed          Journal:  Singapore Med J        ISSN： 0037-5675            Impact factor:   1.858


× No keyword cloud information.
  7 in total

1.  Fasting and bed rest, even for a relatively short period, are risk factors for ceftriaxone-associated pseudolitiasis.

Authors:  Shinya Murata; Tomoki Aomatsu; Atsushi Yoden; Hiroshi Tamai
Journal:  Pediatr Int       Date:  2015-07-21       Impact factor: 1.524

2.  Reversible ceftriaxone-associated biliary pseudolithiasis in children.

Authors:  U B Schaad; J Wedgwood-Krucko; H Tschaeppeler
Journal:  Lancet       Date:  1988-12-17       Impact factor: 79.321

3.  Incidence of ceftriaxone-associated gallbladder pseudolithiasis.

Authors:  F Papadopoulou; S Efremidis; S Karyda; M Badouraki; E Karatza; C Panteliadis; K Malaka
Journal:  Acta Paediatr       Date:  1999-12       Impact factor: 2.299

4.  Ceftriaxone: renal and biliary excretion and effect on the colon microflora.

Authors:  A Arvidsson; G Alván; B Angelin; O Borgå; C E Nord
Journal:  J Antimicrob Chemother       Date:  1982-09       Impact factor: 5.790

5.  Ceftriaxone-induced pseudolithiasis in children treated for perforated appendicitis.

Authors:  Hanna Alemayehu; Amita A Desai; Priscilla Thomas; Susan W Sharp; Shawn D St Peter
Journal:  Pediatr Surg Int       Date:  2014-01-28       Impact factor: 1.827

Review 6.  Gall-bladder sludge: lessons from ceftriaxone.

Authors:  Y S Kim; M F Kestell; S P Lee
Journal:  J Gastroenterol Hepatol       Date:  1992 Nov-Dec       Impact factor: 4.029

7.  Biliary precipitation during ceftriaxone therapy: frequency and risk factors.

Authors:  Ahmet Soysal; Kemal Eraşov; Ihsan Akpinar; Mustafa Bakir
Journal:  Turk J Pediatr       Date:  2007 Oct-Dec       Impact factor: 0.552
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.